TY - JOUR T1 - Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting JF - Pharmacological Reviews JO - Pharmacol Rev SP - 462 LP - 505 DO - 10.1124/pharmrev.120.000236 VL - 74 IS - 3 AU - Hui Lin AU - Frank Geurts AU - Luise Hassler AU - Daniel Batlle AU - Katrina M. Mirabito Colafella AU - Kate M. Denton AU - Jia L. Zhuo AU - Xiao C. Li AU - Nirupama Ramkumar AU - Masahiro Koizumi AU - Taiji Matsusaka AU - Akira Nishiyama AU - Martin J. Hoogduijn AU - Ewout J. Hoorn AU - A.H. Jan Danser A2 - Touyz, Rhian Y1 - 2022/07/01 UR - http://pharmrev.aspetjournals.org/content/74/3/462.abstract N2 - The concept of local formation of angiotensin II in the kidney has changed over the last 10–15 years. Local synthesis of angiotensinogen in the proximal tubule has been proposed, combined with prorenin synthesis in the collecting duct. Binding of prorenin via the so-called (pro)renin receptor has been introduced, as well as megalin-mediated uptake of filtered plasma-derived renin-angiotensin system (RAS) components. Moreover, angiotensin metabolites other than angiotensin II [notably angiotensin-(1-7)] exist, and angiotensins exert their effects via three different receptors, of which angiotensin II type 2 and Mas receptors are considered renoprotective, possibly in a sex-specific manner, whereas angiotensin II type 1 (AT1) receptors are believed to be deleterious. Additionally, internalized angiotensin II may stimulate intracellular receptors. Angiotensin-converting enzyme 2 (ACE2) not only generates angiotensin-(1-7) but also acts as coronavirus receptor. Multiple, if not all, cardiovascular diseases involve the kidney RAS, with renal AT1 receptors often being claimed to exert a crucial role. Urinary RAS component levels, depending on filtration, reabsorption, and local release, are believed to reflect renal RAS activity. Finally, both existing drugs (RAS inhibitors, cyclooxygenase inhibitors) and novel drugs (angiotensin receptor/neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, soluble ACE2) affect renal angiotensin formation, thereby displaying cardiovascular efficacy. Particular in the case of the latter three, an important question is to what degree they induce renoprotection (e.g., in a renal RAS-dependent manner). This review provides a unifying view, explaining not only how kidney angiotensin formation occurs and how it is affected by drugs but also why drugs are renoprotective when altering the renal RAS.Significance Statement Angiotensin formation in the kidney is widely accepted but little understood, and multiple, often contrasting concepts have been put forward over the last two decades. This paper offers a unifying view, simultaneously explaining how existing and novel drugs exert renoprotection by interfering with kidney angiotensin formation. ER -